Results 161 to 170 of about 368,305 (304)

[Digital Technologies in the Community: Key to the Professional Learning of the Future]. [PDF]

Aten Primaria
Hernández Navarro EV, Mayorga Valle FP, Llerena Morales GA, Acosta Nuñez JM, Molina Chifla CL.   +4 more
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

[Economic evaluation in the health sector: The link between economic and health variables]. [PDF]

Rev Med Inst Mex Seguro Soc
Inzunza-Cervantes G, Peña-Valenzuela AN, García-Álvarez CL.   +2 more
europepmc   +1 more source

Comprehensive Assessment of Arterial, Tissue, and Venous Collaterals for Evaluating the Infarct Growth Rate: The Multimodal Collateral Score

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Collaterals are crucial factors that influence the infarct growth rate (IGR). We aimed to determine whether a comprehensive multimodal collateral score (MCS), incorporating collateral assessment at the arterial, tissue, and venous levels, is associated with functional independence and provides incremental prognostic value over ...
Giorgio Busto, Umberto Pensato, Ilaria Casetta, Giorgio U. Marcello, Angelo Barra, Anna Poggesi, Edoardo Carlesi, Sara Mancini, Andrea Ginestroni, Vittorio Miele, Alessandro Padovani, Andrea Morotti, Enrico Fainardi   +12 more
wiley   +1 more source

[Thinking, evaluating, and replenishing the fibrinogen hemostatic strategy in neurosurgery]. [PDF]

Rev Med Inst Mex Seguro Soc
Anica-Malagón ED, Sosa-Bolio JA.
europepmc   +1 more source

Spatial and Volumetric Characteristics of Glioblastoma: Associations With Clinical Presentation and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We aim to comprehensively analyze how regional tumor and edema characteristics are associated with clinical presentations and survival outcomes in a large cohort of glioblastoma patients. Methods Patients with IDH‐wildtype glioblastoma who received brain MRI from 2010 to 2023 were included.
Daniel J. Zhou, Marc Jaskir, Julian Gal, Yombe Fonkeu, Christos Davatzikos, MacLean P. Nasrallah, Jose Garcia, Rubo Xing, Stephen J. Bagley, Arati Desai, Richard E. Phillips, Steven Tobochnik, Colin A. Ellis, James J. Gugger, Nishant Sinha, Joel M. Stein, Kathryn A. Davis   +16 more
wiley   +1 more source

Decisiones de trozado de árboles asistidas por computador

, 1995
páginas 109 ...
Obreque N.,C., Neuenschwander Alvarado, Rodolfo, Cornejo Z.,O., Rivas M.,M.   +3 more
core  

Leadership and Human-AI Collaboration: A Measurement Scale. [PDF]

Behav Sci (Basel)
Acosta-Prado JC, Camargo JP, Zárate-Torres RA, Rey-Sarmiento CF.   +3 more
europepmc   +1 more source

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro, Shiwen Koay, Gordon T. Ingle, Patricia McNamara, Laura Watson, Fion Bremner, Valeria Iodice   +6 more
wiley   +1 more source

[EUROPREV Forum Madrid 2026: «Towards a safe, effective and person-centered prevention»]. [PDF]

Aten Primaria
Camarelles F, Rodriguez-Benito L, Brotons C, Belinchón S, Cotillas A.   +4 more
europepmc   +1 more source